xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

437

ICAR SINONASAL TUMORS

comparison groups. Ann Otol Rhinol Laryngol . 1984;93(5 Pt 1):477-482. https://doi.org/10.1177/000348948409300513 1612. Shao JY, Li YH, Gao HY, et al. Comparison of plasma Epstein Barr virus (EBV) DNA levels and serum EBV immunoglob ulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma. Cancer . 2004;100(6):1162-1170. https://doi.org/10.1002/cncr.20099 1613. Fan H, Nicholls J, Chua D, et al. Laboratory markers of tumor burden in nasopharyngeal carcinoma: a comparison of viral load and serologic tests for Epstein-Barr virus. Int J Cancer . 2004;112(6):1036-1041. https://doi.org/10.1002/ijc.20520 1614. Twu CW, Wang WY, Liang WM, et al. Comparison of the prog nostic impact of serum anti-EBV antibody and plasma EBV DNA assays in nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys . 2007;67(1):130-137. https://doi.org/10.1016/j.ijrobp. 2006.07.012 1615. Lo YM, Chan LY, Lo KW, et al. Quantitative analysis of cell-free Epstein-Barr virus DNA in plasma of patients with nasopharyngeal carcinoma. CancerRes . 1999;59(6):1188-1191. 1616. Lo YM, Chan LY, Chan AT, et al. Quantitative and tempo ral correlation between circulating cell-free Epstein-Barr virus DNA and tumor recurrence in nasopharyngeal carcinoma. CancerRes . 1999;59(21):5452-5455. 1617. Lo YM, Leung SF, Chan LY, et al. Kinetics of plasma Epstein Barr virus DNA during radiation therapy for nasopharyngeal carcinoma. CancerRes . 2000;60(9):2351-2355. 1618. Lo YM, Chan AT, Chan LY, et al. Molecular prognostication of nasopharyngeal carcinoma by quantitative analysis of circu lating Epstein-Barr virus DNA. CancerRes . 2000;60(24):6878 6881. 1619. Chan AT, Lo YM, Zee B, et al. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undif ferentiated nasopharyngeal carcinoma. J Natl Cancer Inst . 2002;94(21):1614-1619. https://doi.org/10.1093/jnci/94.21.1614 1620. Chan KC, Zhang J, Chan AT, et al. Molecular characterization of circulating EBV DNA in the plasma of nasopharyngeal car cinoma and lymphoma patients. CancerRes . 2003;63(9):2028 2032. 1621. Leung SF, Chan AT, Zee B, et al. Pretherapy quantitative measurement of circulating Epstein-Barr virus DNA is predic tive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type. Cancer . 2003;98(2):288-291. https://doi.org/10.1002/cncr.11496 1622. Lin JC, Wang WY, Chen KY, et al. Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopha ryngeal carcinoma. N Engl J Med . 2004;350(24):2461-2470. https://doi.org/10.1056/NEJMoa032260 1623. Ma BB, King A, Lo YM, et al. Relationship between pre treatment level of plasma Epstein-Barr virus DNA, tumor burden, and metabolic activity in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys . 2006;66(3):714-720. https://doi.org/10.1016/j.ijrobp.2006.05.064 1624. Liu Y, Fang Z, Liu L, Yang S, Zhang L. Detection of Epstein Barr virus DNA in serum or plasma for nasopharyngeal cancer: a meta-analysis. Genet Test Mol Biomarkers . 2011;15(7 8):495-502. https://doi.org/10.1089/gtmb.2011.0012 1625. Han BL, Xu XY, Zhang CZ, et al. Systematic review on Epstein-Barr virus (EBV) DNA in diagnosis of nasopharyn-

Forum Allergy Rhinol . 2014;4(8):675-683. https://doi.org/10. 1002/alr.21332 1599. Pathmanathan R, Prasad U, Chandrika G, Sadler R, Flynn K, Raab-Traub N. Undifferentiated, nonkeratinizing, and squa mous cell carcinoma of the nasopharynx. Variants of Epstein Barr virus-infected neoplasia. Am J Pathol . 1995;146(6):1355 1367. 1600. Murono S, Yoshizaki T, Tanaka S, Takeshita H, Park CS, Furukawa M. Detection of Epstein-Barr virus in nasopha ryngeal carcinoma by in situ hybridization and polymerase chain reaction. Laryngoscope . 1997;107(4):523-526. https://doi. org/10.1097/00005537-199704000-00017 1601. Zhao LN, Zhou B, Shi M, et al. Clinical outcome for nasopha ryngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non endemic region of China. Oral Oncol . 2012;48(9):864-869. https://doi.org/10.1016/j.oraloncology.2012.03.001 1602. Cheung F, Chan O, Ng WT, Chan L, Lee A, Pang SW. The prognostic value of histological typing in nasopharyngeal carcinoma. OralOncol . 2012;48(5):429-433. https://doi.org/10. 1016/j.oraloncology.2011.11.017 1603. Zang J, Li C, Zhao LN, et al. Prognostic model of death and distant metastasis for nasopharyngeal carci noma patients receiving 3DCRT/IMRT in nonendemic area of China. Medicine . 2016;95(21):e3794. https:// doi.org/10.1097/md.0000000000003794 1604. Ruuskanen M, Grenman R, Leivo I, et al. Out come of nasopharyngeal carcinoma in Finland: a nationwide study. Acta Oncol . 2018;57(2):251-256. https://doi.org/10.1080/0284186x.2017.1346378 1605. Argirion I, Zarins KR, Ruterbusch JJ, et al. Increasing incidence of Epstein-Barr virus-related nasopharyngeal car cinoma in the United States. Cancer . 2020;126(1):121-130. https://doi.org/10.1002/cncr.32517 1606. Wan SK, Chan JK, Lau WH, Yip TT. Basaloid-squamous car cinoma of the nasopharynx. An Epstein-Barr virus-associated neoplasm compared with morphologically identical tumors occurring in other sites. Cancer . 1995;76(10):1689-1693. https://doi.org/10.1002/1097-0142(19951115)76:10 ⟨ 1689::aid cncr2820761003 ⟩ 3.0.co;2-9 1607. Unsal AA, Booth JR, Rossi NA, Byrd JK, Kountakis SE. Basa loid nasopharyngeal carcinoma: a population-based analysis of a rare tumor. Laryngoscope . 2019;129(12):2727-2732. https:// doi.org/10.1002/lary.27788 1608. Henle W, Henle G, Ho HC, et al. Antibodies to Epstein Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst . 1970;44(1):225-231. 1609. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carci noma. Int J Cancer . 1976;17(1):1-7. https://doi.org/10.1002/ijc. 2910170102 1610. Ho HC, Ng MH, Kwan HC, Chau JC. Epstein-Barr-virus specific IgA and IgG serum antibodies in nasopharyngeal carcinoma. Br JCancer . 1976;34(6):655-660. https://doi.org/10. 1038/bjc.1976.228 1611. Neel HB, Pearson GR, Taylor WF. Antibodies to Epstein Barr virus in patients with nasopharyngeal carcinoma and in